Aethlon Medical to Announce Q1 Financial Results and Host Call on August 14, 2024

Aethlon Medical, Inc., a company specializing in medical therapeutics targeting cancer and severe infectious diseases, has announced the release of its fiscal first-quarter financial results. These results, for the quarter ending June 30, 2024, will be made public at 4:15 p.m. ET on Wednesday, August 14, 2024. Immediately following this release, the company's management will hold a conference call at 4:30 p.m. ET to discuss the financial outcomes and recent corporate progress. This session will conclude with a question and answer segment.

Participants interested in joining the conference can register online, where they will receive their dial-in details upon registration. Those without internet access or who cannot register online can join the call by dialing 1-844-836-8741 (toll-free) or 1-412-317-5442 (international). Participants should reference the Aethlon Medical, Inc. conference call when dialing in. Additionally, a replay of the conference call will be accessible about an hour after the call ends and will remain available until September 14, 2024. The replay can be accessed through Aethlon Medical's website or by calling 1-877-344-7529 for domestic participants, 1-412-317-0088 for international participants, or 1-855-669-9658 for Canada. The replay conference ID number is 3788019.

Aethlon Medical is renowned for developing the Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to treat both cancer and life-threatening viral infections and is also relevant in organ transplantation. The Hemopurifier has shown efficacy in human trials by eliminating life-threatening viruses and, in pre-clinical studies, by removing harmful exosomes from biological fluids using its unique lectin-based technology. The removal of these exosomes is significant for cancer treatment, as they can promote immune suppression and metastasis, and for combating infectious diseases. The Hemopurifier has received the U.S. Food and Drug Administration (FDA) Breakthrough Device designation for treating individuals with advanced or metastatic cancer who are either non-responsive to or intolerant of standard therapies. This designation is also applicable to cancer types in which exosomes contribute to disease development or severity. The device holds another FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) for treating life-threatening viruses not addressed by approved therapies.

In summary, Aethlon Medical continues to make strides in the medical field with the development of its Hemopurifier, a device with the potential to revolutionize the treatment of cancer and severe viral infections. With the upcoming release of their fiscal first-quarter results and the subsequent conference call, stakeholders will have the opportunity to gain deeper insights into the company’s financial health and ongoing projects.